P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY

Introduction. Talquetamab (Tal) is a GPRC5D×CD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Early oral adverse event (AEs) onset, including dysgeusia, can impact patient (pt) quality of life. The TALISMAN study aims to better understand oral AEs be...

ver descrição completa

Detalhes bibliográficos

Principais autores:	R. Popat, N.W.C.J. Van De Donk, B. Faiman, J. Yuda, K. Kim, A. Costa, A. Laheij, R.L. Doty, J. Omel, B. Lipe, L. Sanchez, A. Chari, A. Lin, H. Sroussi, M. Fernandez, K.S. Gray, G. Aguilar, K. Bolyard, J. Schultz, K. Qi, D. Cortes-Selva, J. Zhang, C. Heuck, K. Hawks, K. Tian, M. França, L. Rasche
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2026-04-01
Colecção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/14053
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!